Skip to main content

Advertisement

Table 2 Patients and sequential change of max SUVmax

From: The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy

Pt. # Age Treatment MSKCC classification max SUVmax before treatment max SUVmax at nadir max SUVmax at PD PFS (month) Number of PET/CT evaluation
1 70′s sorefanib favorable 8.1 4.8 9.5 15.0 7
2 60′s sorefanib intermediate 8.2 8.0 8.0 3.2 3
3 50′s sunitnib intermediate 3.9 not decrease 4.0 4.1 3
4 50′s sunitnib intermediate 9.1 0.0 6.2 26.1 13
5 70′s sorefanib intermediate 5.3 2.7 4.6 21.0 9
6 60′s sorefanib intermediate 7.2 5.5 6.3 5.5 4
7 30′s sunitnib favorable 16.1 10.4 15.0 7.8 6
8 60′s sunitnib poor 14.3 12.2 12.2 0.9 2
9 80′s sunitnib intermediate 5.1 not decrease 6.4 2.2 2
10 50′s sunitnib intermediate 5.8 4.2 6.8 7.4 4
11 60′s sunitnib intermediate 8.2 3.4 7.0 6.1 4
12 70′s sorefanib intermediate 2.3 not decrease 4.4 3.6 3
13 80′s sorefanib intermediate 6.9 0.0 7.6 18.5 7
14 50′s sunitnib favorable 5.2 3.6 5.1 19.4 5
15 50′s sunitnib favorable 12.5 4.5 7.8 4.8 3
16 60′s sorefanib favorable 5.2 4.8 7.1 26.2 9
17 70′s sorefanib intermediate 6.5 5.2 5.7 6.5 3
18 60′s sorefanib favorable 4.1 3.6 4.6 6.9 4
19 50′s sorefanib favorable 5.8 4.5 7.8 22.3 7
20 70′s sunitnib intermediate 9.1 3.6 8.1 17.4 7
21 50′s sorefanib poor 9.5 not decrease 12.0 1.4 2
22 60′s sorefanib intermediate 7.4 not decrease 8.8 3.6 3
23 50′s sunitnib intermediate 8.2 5.5 5.5 0.9 2
24 70′s sorefanib intermediate 9.4 7.5 8.5 6.2 4
25 70′s sorefanib intermediate 7.0 5.9 7.6 4.2 3
26 60′s sunitnib poor 8.2 6.4 6.6 3.4 3
27 60′s sorefanib intermediate 5.2 not decrease 6.5 7.0 4
28 70′s sunitnib intermediate 8.4 6.2 7.2 10.7 5
29 50′s sunitnib poor 9.1 9.0 9.0 0.9 2
30 60′s sorefanib favorable 5.6 4.0 4.8 6.9 4
31 50′s sunitnib intermediate 11.0 not decrease 12.8 1.5 2
32 70′s sunitnib intermediate 6.4 4.2 7.0 6.5 4
33 60′s sunitnib intermediate 10.6 10.3 10.3 1.0 2
34 60′s sorefanib intermediate 5.5 not decrease 6.0 4.7 3
35 60′s sorefanib intermediate 10.1 not decrease 13.3 0.9 2
36 60′s sunitnib intermediate 3.7 not decrease 4.8 9.9 5
37 70′s sorefanib favorable 3.9 2.2 4.6 6.5 3
38 60′s sunitnib intermediate 7.9 5.2 6.7 2.9 4